Opinion|Videos|May 15, 2024
Recent Insights into the Pathophysiology of Alzheimer Disease
B. Joy Snider, MD, PhD, gives an overview of the pathophysiology of Alzheimer disease, highlighting recent advances in the field.
Advertisement
Episodes in this series
- What is the role of amyloid β deposits, amyloid oligomer formation, and tau proteinsin the development and progression of the disease, and what new advances have we learned in the last 3 to 5 years?
Advertisement
Related to this article
Jennifer Flythe, MD, MPH, discusses individualizing dialysis volume management and why guideline-directed therapy use lags in advanced CKD.
Povetacicept reduced proteinuria by 52% vs 4.3% with placebo at week 36 in adults with IgA nephropathy in the phase 3 RAINIER trial’s interim analysis.
Outpatient dialysis for unfunded patients with ESKD cut ED reliance and costs, while church-based CKD screening improved blood pressure.
Asian expert consensus updates mantle cell lymphoma treatment guidelines, highlighting uneven BTK inhibitor, ibrutinib and CAR T-cell access across Asia.
At ASN Kidney Week 2026, nephrologists said value-based kidney models improved dialysis starts, but payment cuts and MA growth are pushing practices out.
At IDWeek 2026, IDSA and HIVMA leaders and clinician advocates outline how stories, relationships, and bipartisan outreach shape ID and HIV policy.
Insulin icodec-abae becomes the first once-weekly basal insulin cleared for children 10 years and older with type 2 diabetes.
At IDWeek 2026, Atul Gawande, MD, MPH, said USAID cuts are costing lives but that the field is "not back at square one."
Advertisement
Advertisement
Trending on AJMC
1
Nephrologists Weigh Wins, Losses From 5 Years of Value-Based Kidney Care
2
Povetacicept Cuts Proteinuria by 52% in IgA Nephropathy at Week 36
3
Merck, Moderna Cancer Vaccine Cuts Melanoma Recurrence Risk by 42%
4
Dialysis Access, Church CKD Screening Address Kidney Care Inequities
5